Substituted heterocycle fused gamma-carbolines
US6552017B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 15, 2000 |
| Grant date | Apr 22, 2003 |
| Priority date | — |
| Expiry date | Jun 15, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.